Skip to main content

Advertisement

Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis

Abstract

Background

Screening is an important part of preventive medicine. Ideally, screening tools identify patients early enough to provide treatment and avoid or reduce symptoms and other consequences, improving health outcomes of the population at a reasonable cost. Cost-effectiveness analyses combine the expected benefits and costs of interventions and can be used to assess the value of screening tools.

Objective

This review seeks to evaluate the latest cost-effectiveness analyses on screening tools to identify the current challenges encountered and potential methods to overcome them.

Methods

A systematic literature search of EMBASE and MEDLINE identified cost-effectiveness analyses of screening tools published in 2017. Data extracted included the population, disease, screening tools, comparators, perspective, time horizon, discounting, and outcomes. Challenges and methodological suggestions were narratively synthesized.

Results

Four key categories were identified: screening pathways, pre-symptomatic disease, treatment outcomes, and non-health benefits. Not all studies included treatment outcomes; 15 studies (22%) did not include treatment following diagnosis. Quality-adjusted life years were used by 35 (51.4%) as the main outcome. Studies that undertook a societal perspective did not report non-health benefits and costs consistently. Two important challenges identified were (i) estimating the sojourn time, i.e., the time between when a patient can be identified by screening tests and when they would have been identified due to symptoms, and (ii) estimating the treatment effect and progression rates of patients identified early.

Conclusions

To capture all important costs and outcomes of a screening tool, screening pathways should be modeled including patient treatment. Also, false positive and false negative patients are likely to have important costs and consequences and should be included in the analysis. As these patients are difficult to identify in regular data sources, common treatment patterns should be used to determine how these patients are likely to be treated. It is important that assumptions are clearly indicated and that the consequences of these assumptions are tested in sensitivity analyses, particularly the assumptions of independence of consecutive tests and the level of patient and provider compliance to guidelines and sojourn times. As data is rarely available regarding the progression of undiagnosed patients, extrapolation from diagnosed patients may be necessary.

Background

Screening represents a cornerstone of preventive medicine. Its rationale is to identify disease during an early and pre-symptomatic stage [1]. With appropriate treatment, screening can result in disease prevention for those patients identified as at-risk. Early disease may be easier and less expensive to treat, which positions screening strategies as potentially sound investments for healthcare systems. Several countries have developed national screening programs that have led to increased disease detection rates and prevention [2, 3].

However, screening is not entirely risk-free and usually represents an immediate economic burden for systems with tight budget constraints. Some screening tools are associated with direct health risks (X-rays and radiation), and others might not provide a real additional value if, for instance, no follow-up treatment is available [1]. Additionally, tests need to be sufficiently reliable and accurate, since high proportions of false negatives or false positives might represent worse health outcomes and unnecessary diagnostic costs [4, 5]. To maximize value, an economic evaluation is a useful tool to compare the potential benefits, risks, and costs of different strategies and to inform resource allocation decisions. All health systems have scarce resources and are faced with opportunity costs; this means that any investment in a screening tool will come at the cost of other health services to the detriment of those patients who would have been treated [6].

Recognizing opportunity costs, healthcare systems may require that health interventions are both clinically and cost-effective to be considered for implementation [7]. Cost-effectiveness analysis (CEA) can be trial-based evaluations that use trial data to compare alternatives [8]; however, they are expensive to conduct and often require large sample sizes to obtain sufficient statistical power [9]. To overcome these challenges, model-based economic evaluations of screening tools have become a commonplace. Inputs are obtained from the best available sources and combined in mathematical models that replicate patient use of different strategies and provide a summary of costs and consequences for further analysis and comparison [10]. However, given that screening tools are used early in the treatment pathway, economic evaluations of screening strategies have many specific challenges to overcome. The objective of this study is to provide an overview of the different types of challenges and methodologies reported in the most recent cost-effectiveness analyses of screening strategies.

Methods

Eligibility criteria

A systematic review was conducted to identify the latest cost-effectiveness analyses (CEAs) of screening tools. Review and reporting followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [11]. Only research articles published in English and in 2017 were eligible for inclusion. CEAs comparing screening strategies versus no screening or other alternatives were included. There were no exclusion criteria based on the disease area. However, studies focusing on genomic screening and screening for blood transfusion, cost-benefit and cost-minimization studies, and review articles, editorial letters, news, study protocols, case reports, posters, and conference abstracts were excluded.

Searches and study selection

We searched the online databases of EMBASE and MEDLINE. Search terms included Medical Subject Headings (MeSH), Emtree, and keywords for “mass screening” or screening, economic evaluation, and cost-effectiveness analysis. The last search was run on August 17, 2017. The search strategies can be found in Appendix 1 and Appendix 2. Two independent authors (NI and ES) screened all titles and abstracts. Any reference included by either reviewers at this stage was included for full-text review. This section was conducted independently and in duplicate. Disagreements at this stage were settled by discussion until a consensus was reached by both authors (NI and ES).

Data extraction

We extracted the study characteristics and findings including the population, disease/condition, screening tools (strategies), comparators, perspective, time horizon, discounting, outcome or effectiveness measures (i.e., expected life years, quality-adjusted life years, cases detected), and incremental cost-effectiveness ratios (ICERs). A description of the findings was portrayed in a narrative synthesis. Results were compared to an economic evaluation focused on the early diagnosis and treatment of psoriatic arthritis (PsA) that is currently being developed by the authors (NI and ES).

Results

A total of 1059 records were found after 109 duplicates were removed. Two hundred nineteen articles were included for full-text assessment after 840 were excluded during the abstract screening stage (Fig. 1). Finally, 68 economic evaluations of screening tools were narratively synthesized (Table 1). A total of 26 studies (38.2%) evaluated the screening tools for cancer, 6 (8.8%) for hepatic disease, 5 (7.3%) for sexually transmitted disease, and 4 (5.8%) for heart disease. Twenty-nine (42.6%) added a “no screening” alternative for comparison. Thirty-five (51.4%) used quality-adjusted life years (QALYs) as the main outcome. Fifty-three studies (77.9%) modeled treatment options that followed screening and diagnostic testing. Finally, 7 studies (10.3%) concluded that the screening tool(s) they were evaluating were not cost-effective compared to current practice. The rest concluded that the implementation of screening tools had a high probability of being cost-effective. However, some specific recommendations regarding target populations, cost-effectiveness thresholds, and screening frequencies were made by some CEAs. Reported challenges and limitations of the economic evaluations were divided into three categories. The first one pertains to the screening pathway. It takes into account the test availability and sequencing, treatment options, accuracy, and patient compliance. The second describes the pre-symptomatic disease, prevalence, progression, and treatment effects. Finally, challenges with non-health benefits and spillovers are reported.

Fig. 1
figure1

PRISMA flowchart. The PRISMA flow diagram details the search and study inclusion/exclusion process. It is a graphical representation of the flow of citations throughout the review

Table 1 Study characteristics

Screening pathway

The value of the screening test is dependent on the full screening pathway. This refers to the screening test and the subsequent follow-up undertaken because of the results of the screening. The review identified multiple studies that evaluated different screening pathways by modifying the order in which screening tests were administered [12,13,14,15,16,17]. This allowed investigators to determine trade-offs between potential screening sequences. However, these models are dependent on data availability, and lots of different types of evidence are necessary to inform the screening pathway including screening and diagnostic test accuracy and screening compliance. Most studies explored challenges such as conditional test accuracy, a lack of a diagnostic gold standard, outcomes of false positives and false negatives, or screening compliance.

Accuracy

Twenty-five studies (36.7%) explicitly reported challenges regarding screening test accuracy [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43]. One common challenge was the lack of data on test accuracy. In some cases, authors had to assume the accuracy of the screening test [28, 30, 32, 33]; more commonly, it was assumed that tests had the same performance regardless of prior testing [19, 34]. This assumption is particularly important when different sequences of screening and diagnostics tests are being evaluated. Accuracy assumptions were often tested using different combinations of sensitivity and specificity. Barzi et al. modeled a hypothetical test and, through model iterations, determined the combination of test sensitivity and specificity that would yield optimal results in terms of cost-effectiveness [19]. Crowson et al. undertook a two-way sensitivity analysis of sensitivity and specificity to determine their importance to health outcomes and costs [23]. Sensitivity analyses are useful tools to evaluate the uncertainty around test accuracy estimates. These analyses allow a threshold to be determined at which a specific screening tool would result in a cost-effective strategy.

To understand the implications of screening on patients’ health, it is important to model the outcomes of any follow-up diagnostic tests. However, one common difficulty is that there is usually no information on the accuracy of the diagnostic test in the screen-positive population. A few assumptions were made to account for this uncertainty. A study in Thailand for non-alcoholic fatty liver disease used pooled estimates of diagnostic accuracy from a meta-analysis assuming independence between the screening and diagnostic accuracy [33]. Chowers et al. tested different accuracy rates for HIV diagnostic tests with sensitivity analyses [21]. Other studies assumed specific accuracy estimates (usually 100%) and acknowledged the limitations, such as potentially overestimating cost-effectiveness estimates by excluding pertinent costs associated to misclassified patients [22, 29, 44].

False positive and negative outcomes

Screening and diagnostic accuracy determines the proportion of patients who will continue to receive treatment or further follow-up. It is important to understand the health outcomes of all patients screened. Patients identified as false positive or false negative are particularly difficult to consider in cost-effectiveness analysis given the lack of data on these patients. Costs and outcomes for patients who followed incorrect screening and treatment pathways were included in 22 (32.3%) of the studies [12, 17, 18, 21, 23,24,25, 29, 36, 40, 42, 43, 45,46,47,48,49,50,51,52,53,54]. Even though some cost-effectiveness analyses identified false positives in the screening pathways, one alternative was to assume 100% accurate diagnostic tests; this meant patients identified incorrectly during screening would never go on to inappropriate treatment [29, 42, 49]. In these cases, there were extra diagnostic costs, but no treatment-specific costs or outcomes were pertinent. Health outcomes may be overestimated when assuming 100% accurate diagnostic tests. Alternatively, some studies assumed that diagnostic tests were not perfect and included costs and health consequences of the incorrect treatment of false positive patients, such as healthy patients receiving unnecessary treatment and having side effects [17, 43, 48, 53, 54]. Whenever a treatment poses a considerable threat to false positives (or a considerable monetary cost), CEAs should acknowledge and include these scenarios. When false negative patients were modeled, it was assumed that they would progress at the same rate as untreated patients and were usually identified as being sick once symptoms appear [17, 21, 45, 46, 48]. This is comparable to the pathway for all sick patients under a “no screening” arm. A high proportion of false negatives (i.e., tests with low sensitivity) will translate to fewer identified sick patients. Depending on the disease, tests, costs, and health outcomes, a CEA could evaluate whether repeated testing is worth implementing to reduce this proportion of patients. Four studies failed to model false positives and/or negatives after acknowledging their potential effect to the evaluation [12, 18, 25, 36].

Compliance

Screening pathways are greatly altered by different rates of participation and compliance. Screening is only effective if the target population and healthcare providers are engaged. Twenty-nine evaluations (42.6%) identified patient participation and compliance as an important model parameter [12, 14, 16,17,18,19,20, 25, 27, 28, 32, 36, 37, 43,44,45,46, 48,49,50,51, 55,56,57,58,59,60,61,62]. Morton et al. reported that the results of a national breast cancer screening program in the UK would be impacted by the proportion of the at-risk population who decided to participate [50]. Lower compliance translates to lower screening and diagnostic costs, but also represents a higher burden of disease if non-compliers are diagnosed at later and more expensive-to-treat stages of disease. Screening can also raise costs without improving health outcomes if identified patients fail to follow further recommended treatment due to unreliable testing. John et al. also modeled non-compliers who had a chance of getting sick and being identified by opportunistic screening [48]. Additionally, studies such as that conducted by Aronsson et al. explain how compliance rates are dependent on the screening tool to be evaluated [12, 19]. They model colonoscopy and fecal immunochemical tests (FIT) to screen for colorectal cancer, and take into account the different compliance rates for each alternative. Since colonoscopy is expected to make people more uncomfortable than the FIT, less people are expected to comply with the former [12, 19]. To test this, willingness-to-pay to avoid colonoscopy was estimated [12]. However, information about the compliance rates for different screening tests was rarely available. Ten studies (14.7%) assumed a 100% compliance rate [17, 25, 27, 28, 32, 45, 51, 55, 57, 59, 63]. The effect of this assumption over cost-effectiveness estimates depends on the specific evaluation being conducted, specifically the trade-off between lower screening costs and worse health outcomes due to unidentified disease.

Pre-symptomatic disease

Disease prognosis and patient evolution from pre-symptomatic stages of disease were modeled in most cases to estimate aggregate costs and outcomes. All included studies but 2 (3%) [38, 64] explicitly commented on challenges encountered while trying to adequately model disease progression and patient transition through health states. Pre-symptomatic disease refers to the point in progression when the disease is developing but no symptoms are apparent. This is the point when screening tools are useful but usually when there is very little data about progression of the disease. Once identified as having a disease, more data is available for modeling cost-effectiveness.

Prevalence/incidence

Screening models often focus on at-risk populations. Incidence rates are used to determine the proportion of patients who enter the models at pre-symptomatic stages. This is useful for scenarios with repeated screening procedures, as a dynamic model can be developed to evaluate repeated screening processes while taking into account new at-risk patients [47]. On the other hand, some studies included population-specific incidence rates [19, 35, 47]. A different approach consists on evaluating one-time-only screening procedures targeting prevalent disease [49]. Deciding between repeated versus one-time testing depends on the type of disease and population of the evaluation. A one-time test for tuberculosis might be appropriate for immigrant populations, while testing for lung cancer among smokers is recommended to be carried out repeatedly. The sequence and frequency of tests can be tested through modeling to determine the cost-effective option. Sensitivity analyses determined that cost-effectiveness estimates were highly sensitive to changes in prevalence and incidence estimates [25, 49, 65]. Testing for a rare disease might not result cost-effective compared to a common disease given a similar health and economic burden.

Pre-symptomatic disease progression

Once an at-risk population is identified, some cost-effectiveness analyses focused on modeling the pre-symptomatic stages of disease. There is a time interval before clinical symptoms appear and after disease onset where disease is identifiable by screening tools. This timeframe, also called sojourn time, is a major challenge for CEA since progression of pre-symptomatic disease if often unknown (Table 2). Uncertainty around sojourn time was tested by 3 studies (4.4%) [36, 60, 66]. van Luijt et al. determined a fixed preclinical stage of breast cancer where disease could be identified by screening [67]. This study also allowed for disease regression or progression to more advanced pre-symptomatic stages. Atkin et al. modeled similar pre-symptomatic stages for colorectal cancer and adenoma [18]. Sensitivity analyses allowed to estimate the effect of varying the interval for sojourn time on cost-effectiveness. These studies concluded that longer sojourn time represented improved disease identification rates.

Table 2 Summary of methodological issues and suggestions to develop CEAs of screening tools

Modeling patient progression during the sojourn time, i.e., through pre-symptomatic health states, remains a challenge. Three studies extrapolated progression rates from symptomatic disease stages to pre-symptomatic disease [18, 56, 68]. In some cases, fast progressing disease may cause death before diagnosis. Death rates for pre-symptomatic disease were available for colorectal cancer using Kaplan-Meier estimators from lifetime data [18], health state-specific mortality risks in chronic kidney disease [69], and gastric cancer [62]. Additionally, based on differential progression rates and life expectancy, two studies evaluated the potential effect of lead time bias in their studies [35, 54]. This bias explains how early diagnosed patients might not experience an increase in expected survival, but instead spend longer periods under treatment. This effect gives the illusion of higher survival expectancy [35], resulting in biased cost-effectiveness estimates. Survival has a major impact over health-related outcomes in CEAs, and assuming a higher rate will overestimate the health benefits. This is one example of a model input that is likely to affect the cost-effectiveness of a screening tool and should be tested in sensitivity analyses. Yang et al. used population matching (cancer cases vs general population) and a difference in difference methodology to determine if early diagnosis provided improved life expectancy [54]. Both studies showed differential survival rates favoring patients who were diagnosed early after accounting for potential lead time bias [35, 54].

Treatment effect and health outcomes

According to the WHO, screening interventions are expected to provide treatment alternatives for those patients with identified cases of disease [1]. However, 15 studies (22%) failed to model a treatment pathway [22,23,24, 26, 29, 31, 38, 44, 57, 64, 70,71,72,73,74]. The main outcomes captured by these studies were the following: cases detected, missed cases, avoided cases, and identified true positives and true negatives. Decision trees were most commonly used for these modeling tasks. However, these models are insufficient for making reimbursement decisions, since efficacious interventions or therapies are required to follow screening and diagnostic procedures to improve patients’ health. Without these benefits, screening procedures are not capturing all consequences, leading to incomplete CEAs. On the other hand, studies that modeled treatment pathways captured different health outcomes to evaluate cost-effectiveness of screening strategies. Quality-adjusted life years (QALYs) were estimated by 39 studies (57.3%) [12,13,14,15, 17, 18, 21, 27, 28, 32,33,34,35, 37, 39, 40, 42, 45,46,47,48,49,50,51, 53,54,55,56,57, 59, 62, 65, 67,68,69, 72, 74,75,76,77,78], and expected life years (ELYs) by 10 (14.7%) [18, 19, 36, 43, 52, 58, 65, 66, 79, 80]. Utilities were widely used, and the following challenges and methodologies were reported: Chowers et al. acknowledged having underestimated QALY outcomes in their prenatal HIV screening evaluation by excluding maternal utility measures. Additionally, treatment for false positives and its repercussions were excluded, even though treatment for healthy newborns is expected to cause disutility [21]. Ferguson et al. observed there was a difficulty assigning utilities for patients with undiagnosed chronic kidney disease. Therefore, they assumed similar utilities for undiagnosed and diagnosed cases [69]. Cheng et al. extrapolated already estimated utility weights for pre-symptomatic hepatitis A to model the preclinical stage of hepatitis E [76]. Assumptions around utility estimates are common, but require careful consideration to avoid a deviation from the initial target population. Although health outcomes are most often captured after treatment begins, some models included screening and diagnostic specific health effects. Risk of perforation due to colonoscopy was included by Atkin et al. in their colorectal cancer CEA [18]. Yang et al. included radiation-induced cancer cases from radiography screening [54]. Failing to include potentially negative health effects of screening tests will overestimate the health benefits and potentially underestimate associated costs.

Some studies reported uncertainty around treatment efficacy inputs [15, 44, 65, 66, 75]. Sensitivity and scenario analyses were broadly used to account for this uncertainty. Not surprisingly, cost-effectiveness estimates were influenced by treatment efficacy of early treatment and uptake [65, 66, 75]. A few studies conducted a value of information analyses to estimate the value of collecting further information to resolve decision uncertainty [18, 44, 75].

Non-health costs and outcomes, and spillovers

CEAs take into account the costs and outcomes of specific interventions and compare them to determine if they provide enough benefits relative to the cost compared to the next best alternative. However, not all potential benefits and costs are necessarily health related. The perspective of a CEA determines what kind of effects and costs will be included. A healthcare perspective seeks to compare costs and consequences that directly pertain to the healthcare sector. They generally focus on health-related outcomes [81]. Alternatively, a societal perspective attempts to capture all relevant costs and outcomes, health-related or not. Transportation costs, out-of-pocket expenses, and productivity losses are a few examples. These analyses evaluate the trade-off between health and any other outcome, but this information is rarely known, i.e., societal preferences between health and productivity or educational benefits [81]. This review identified 38 (55.8%) and 15 (22%) studies that developed their analyses under a healthcare [12, 14, 18, 20,21,22,23, 25, 27, 29, 34,35,36,37,38,39,40, 42, 44, 46,47,48,49,50,51,52,53,54,55, 58, 60, 62, 65, 66, 68, 69, 75, 78] and societal perspective [13, 15, 17, 19, 28, 33, 41, 43, 56, 57, 59, 61, 67, 76, 80], respectively. The following were specific studies that included non-health costs and/or outcomes: Cressman et al. estimated the productivity loss of lung cancer patients who had been previously working before starting treatment [56]. Phisalprapa et al. included non-medical costs (transportation, meals, accommodations, and facilities) in their evaluation of non-alcoholic fatty liver disease [33]. Pil et al. used a patient questionnaire to assess indirect costs in their skin cancer screening CEA related to productivity loss, morbidity, and early mortality [59]. Sharma et al. included patient transportation costs [61]. The decision to include indirect (or non-medical) costs and outcomes depends on the decision maker’s perspective. The societal perspective allows a thorough analysis by including a broader spectrum of the associated consequences. However, including all indirect outcomes or externalities might prove a difficult task, and missing important outcomes will render the evaluation incomplete and possibly biased. It is also true that although most studies considering a societal perspective focused on costs, there was one that also included non-health benefits or outcomes. Chen et al. compared the benefits of the different types of education that children received after being screened and treated for neonatal hearing loss. Children who were successfully identified and treated for hearing loss were expected to have better educational outcomes [45]. Sensitivity analyses determined that cost-effectiveness estimates were most affected by the inclusion of the societal costs [80].

One concern of adopting a societal perspective is the implicit assumptions on how resources should be distributed; for example, including productivity costs (an important part of non-health outcomes) generally benefits treatments of the working age population at the cost of children and seniors [82]. Prusa et al. developed a CEA of toxoplasmosis screening for children in Austria. Besides considering the projected lifetime productivity loss of the affected children, they also considered the productivity loss of parents [80]. Consequences (health-related or not) that fall on third or external parties are called spillover effects [83]. Spillover effects were not identified or modeled in any other study. Basu and Meltzer argue that CEAs might better reflect all associated costs and outcomes by considering spillovers [83]. CEAs that focus on screening tools have specific challenges to address regarding spillovers or externalities, especially health-related ones. False positive tests for venereal diseases, for instance, can have negative consequences for families and third parties in terms of anxiety, stress, and divorce. On the other hand, there are potential positive spillovers. For example, screening tests might have a modest capacity to identify similar conditions. This review did not identify studies that included benefits of such opportunistic identification.

Discussion

This study reviewed the latest CEAs of screening tools and provided a thorough breakdown of challenges and suggestions to overcome them. The included studies mentioned several assumptions and methodological alternatives that were grouped in four major categories: the screening pathway, pre-symptomatic disease, treatment outcomes, and spillovers and externalities. To capture all important costs and outcomes of a screening tool, screening pathways should be modeled through the treatment of the patient. Also, false positive and false negative patients are likely to have important costs and benefits and should be included in the analysis. As these patients are difficult to identify in regular data sources, common treatment patterns should be used to determine how these patients are likely to be treated. Many assumptions are needed when modeling screening tools. It is important that these assumptions are clearly indicated and that the consequences of these assumptions are tested in sensitivity analyses. These include the assumptions such as the independence of consecutive tests and the level of patient and provider compliance to guidelines and sojourn times, i.e., the time between when a patient can be identified by screening test and when they would have been identified due to symptoms. As data is rarely available regarding the progression of undiagnosed patients, extrapolation from diagnosed patients may be necessary. Not surprisingly, different scenarios concluded that longer sojourn times were likely to result in improved health outcomes. This becomes one of the main drivers of the effectiveness of a screening test, besides the accuracy at which it identifies patients correctly. This was particularly true when available treatment was capable of modifying disease progression. Finally, non-health costs and outcomes were observed for studies that developed their analyses under a societal perspective. These were not consistently reported, mostly likely due to different guidelines from decision makers.

This review thoroughly examined the latest methodological challenges associated with modeling CEAs of screening tools. However, some limitations are to be noted. Studies focusing on genomic and blood transfusion screening tests were excluded. Genomic screening was excluded because a recent paper evaluated CEAs of genomic screening tests [84]. Blood transfusion tests were excluded because different issues arise when testing blood for treatment rather than testing patients for disease [85]. Challenges and methodologies of CEAs are expected to vary considerably between these groups. Finally, studies were limited to 2017 to capture the most recent state of the art in this area. We were interested in the latest available evidence to appropriately review the most up-to-date methodologies for modeling screening tools from a health economic perspective. However, all diseases were included to avoid disease-specific issues and to provide a broad learning across disease areas.

Conclusion

Many new screening tools are being developed and require cost-effectiveness analyses to support their value proposition. Screening tools should follow diagnostic guidelines, but have additional challenges given that sojourn times and pre-symptomatic progression data is rarely known. Current cost-effectiveness analyses extrapolate pre-symptomatic progression from symptomatic patients and thoroughly test assumptions in sensitivity analyses, including sojourn times. By following these methodological suggestions, screening tool evaluations are expected to become a better reflection of medical practice and to provide better quality evidence for decision makers making difficult trade-offs between funding screening interventions or other health technologies.

References

  1. 1.

    Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65(4):281–393.

  2. 2.

    Blanks RG, Wallis MG, Moss SM. A comparison of cancer detection rates achieved by breast cancer screening programmes by number of readers, for one and two view mammography: results from the UK National Health Service breast screening programme. J Med Screen. 1998;5(4):195–201.

  3. 3.

    van Velzen CL, Clur SA, Rijlaarsdam ME, Bax CJ, Pajkrt E, Heymans MW, et al. Prenatal detection of congenital heart disease—results of a national screening programme. BJOG. 2016;123(3):400–7.

  4. 4.

    Petticrew MP, Sowden AJ, Lister-Sharp D, Wright K. False-negative results in screening programmes: systematic review of impact and implications. Health Technol Assess. 2000;4(5):1–120.

  5. 5.

    Tosteson AN, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, et al. Consequences of false-positive screening mammograms. JAMA Intern Med. 2014;174(6):954–61.

  6. 6.

    Drummond M, Weatherly H, Ferguson B. Economic evaluation of health interventions. BMJ. 2008;337:a1204.

  7. 7.

    McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733–44.

  8. 8.

    van Dongen JM, van Wier MF, Tompa E, Bongers PM, van der Beek AJ, van Tulder MW, et al. Trial-based economic evaluations in occupational health: principles, methods, and recommendations. J Occup Environ Med. 2014;56(6):563–72.

  9. 9.

    Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? PharmacoEconomics. 2000;17(5):445–59.

  10. 10.

    Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—modeling studies. Value Health. 2003;6(1):9–17.

  11. 11.

    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.

  12. 12.

    Aronsson M, Carlsson P, Levin LA, Hager J, Hultcrantz R. Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer. Br J Surg. 2017;104(8):1078–86.

  13. 13.

    Bleijenberg N, Drubbel I, Neslo RE, Schuurmans MJ, Ten Dam VH, Numans ME, et al. Cost-effectiveness of a proactive primary care program for frail older people: a cluster-randomized controlled trial. J Am Med Dir Assoc. 2017;18(12):1029–36. e3

  14. 14.

    Ethgen O, Sanchez Gonzalez Y, Jeanblanc G, Duguet A, Misurski D, Juday T. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population. J Med Econ. 2017;20(2):162–70.

  15. 15.

    Mo X, Gai Tobe R, Wang L, Liu X, Wu B, Luo H, et al. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017;17(1):502.

  16. 16.

    Petry KU, Barth C, Wasem J, Neumann A. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany. Eur J Obstet Gynecol Reprod Biol. 2017;212:132–9.

  17. 17.

    Wang H, Yang L, Wang F, Zhang L. Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease. BMC Nephrol. 2017;18(1):135.

  18. 18.

    Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, et al. The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. Health Technol Assess. 2017;21(25):1–536.

  19. 19.

    Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017;123(9):1516–27.

  20. 20.

    Campos NG, Sharma M, Clark A, Lee K, Geng F, Regan C, et al. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. Int J Gynaecol Obstet. 2017;138(Suppl 1):47–56.

  21. 21.

    Chowers M, Shavit O. Economic evaluation of universal prenatal HIV screening compared with current ‘at risk’ policy in a very low prevalence country. Sex Transm Infect. 2017;93(2):112–7.

  22. 22.

    Coyle K, Carrier M, Lazo-Langner A, Shivakumar S, Zarychanski R, Tagalakis V, et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res. 2017;151:67–71.

  23. 23.

    Crowson MG, Rocke DJ, Hoang JK, Weissman JL, Kaylie DM. Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss. Neuroradiology. 2017;59(8):727–36.

  24. 24.

    Devine A, Harvey R, Min AM, Gilder MET, Paw MK, Kang J, et al. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC Infect Dis. 2017;17(1):552.

  25. 25.

    Ditkowsky J, Shah KH, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA. Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States. BMC Infect Dis. 2017;17(1):155.

  26. 26.

    Ferrandiz L, Ojeda-Vila T, Corrales A, Martin-Gutierrez FJ, Ruiz-de-Casas A, Galdeano R, et al. Internet-based skin cancer screening using clinical images alone or in conjunction with dermoscopic images: a randomized teledermoscopy trial. J Am Acad Dermatol. 2017;76(4):676–82.

  27. 27.

    Goede SL, Rabeneck L, van Ballegooijen M, Zauber AG, Paszat LF, Hoch JS, et al. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLoS One. 2017;12(3):e0172864.

  28. 28.

    Gupta N, Langenderfer D, McCormack FX, Schauer DP, Eckman MH. Chest computed tomographic image screening for cystic lung diseases in patients with spontaneous pneumothorax is cost effective. Ann Am Thorac Soc. 2017;14(1):17–25.

  29. 29.

    Heidari S, Manesh AO, Rajabi F, Moradi-Joo M. Cost-effectiveness analysis of automated auditory brainstem response and Otoacoustic emission in universal neonatal hearing screening. Iran J Pediatr. 2017;27(2):e5229. https://doi.org/10.5812/ijp.5229.

  30. 30.

    Horn BP, Crandall C, Forcehimes A, French MT, Bogenschutz M. Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments. J Subst Abus Treat. 2017;79:6–11.

  31. 31.

    Hunter SA, Morris C, Nelson K, Snyder BJ, Poulton TB. Digital breast tomosynthesis: cost-effectiveness of using private and Medicare insurance in community-based health care facilities. AJR Am J Roentgenol. 2017;208(5):1171–5.

  32. 32.

    Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD. Cost-effectiveness of cardiovascular screening in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2017;69(2):175–82.

  33. 33.

    Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, et al. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Med (Baltimore). 2017;96(17):e6585.

  34. 34.

    Requena-Mendez A, Bussion S, Aldasoro E, Jackson Y, Angheben A, Moore D, et al. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. Lancet Glob Health. 2017;5(4):E439–E47.

  35. 35.

    Saito S, Azumi M, Muneoka Y, Nishino K, Ishikawa T, Sato Y, et al. Cost-effectiveness of combined serum anti-helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. Eur J Health Econ. 2017; https://doi.org/10.1007/s10198-017-0901-y.

  36. 36.

    Schiller-Fruehwirth I, Jahn B, Einzinger P, Zauner G, Urach C, Siebert U. The long-term effectiveness and cost effectiveness of organized versus opportunistic screening for breast cancer in Austria. Value Health. 2017;20(8):1048–57.

  37. 37.

    Tjalma WAA, Kim E, Vandeweyer K. The impact on women’s health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium. Eur J Obstet Gynecol Reprod Biol. 2017;212:171–81.

  38. 38.

    Tufail A, Rudisill C, Egan C, Kapetanakis VV, Salas-Vega S, Owen CG, et al. Automated diabetic retinopathy image assessment software: diagnostic accuracy and cost-effectiveness compared with human graders. Ophthalmol. 2017;124(3):343–51.

  39. 39.

    Meulen MPV, Kapidzic A, Leerdam MEV, van der Steen A, Kuipers EJ, Spaander MCW, et al. Do men and women need to be screened differently with fecal immunochemical testing? A cost-effectiveness analysis. Cancer Epidemiol Biomark Prev. 2017;26(8):1328–36.

  40. 40.

    Welton NJ, McAleenan A, Thom HH, Davies P, Hollingworth W, Higgins JP, et al. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2017;21(29):1–236.

  41. 41.

    Williams DM, Miller AO, Henry MW, Westrich GH, Ghomrawi HMK. Cost-effectiveness of Staphylococcus aureus decolonization strategies in high-risk total joint arthroplasty patients. J Arthroplast. 2017;32(9S):S91–S6.

  42. 42.

    Yarnoff BO, Hoerger TJ, Simpson SK, Leib A, Burrows NR, Shrestha SS, et al. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol. 2017;18(1):85.

  43. 43.

    Zimmermann MR, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, et al. Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya. Cost Eff Resour Alloc. 2017;15:13.

  44. 44.

    Haukaas FS, Arnesen TM, Winje BA, Aas E. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. Eur J Health Econ. 2017;18(4):405–15.

  45. 45.

    Chen X, Yuan M, Lu J, Zhang Q, Sun M, Chang F. Assessment of universal newborn hearing screening and intervention in Shanghai, China. Int J Technol Assess Health Care. 2017;33(2):206–14.

  46. 46.

    Devine A, Parmiter M, Chu CS, Bancone G, Nosten F, Price RN, et al. Using G6PD tests to enable the safe treatment of plasmodium vivax infections with primaquine on the Thailand-Myanmar border: a cost-effectiveness analysis. PLoS Negl Trop Dis. 2017;11(5):e0005602.

  47. 47.

    Gray E, Donten A, Karssemeijer N, van Gils C, Evans DG, Astley S, et al. Evaluation of a stratified National Breast Screening Program in the United Kingdom: an early model-based cost-effectiveness analysis. Value Health. 2017;20(8):1100–9.

  48. 48.

    John D, Parikh R. Cost-effectiveness and cost utility of community screening for glaucoma in urban India. Public Health. 2017;148:37–48.

  49. 49.

    Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, et al. Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea. PLoS One. 2017;12(1):e0167770.

  50. 50.

    Morton R, Sayma M, Sura MS. Economic analysis of the breast cancer screening program used by the UK NHS: should the program be maintained? Breast Cancer (Dove Med Press). 2017;9:217–25.

  51. 51.

    Mullie GA, Schwartzman K, Zwerling A, N'Diaye DS. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC Med. 2017;15(1):104.

  52. 52.

    Ten Haaf K, Tammemagi MC, Bondy SJ, van der Aalst CM, Gu S, SE MG, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada. PLoS Med. 2017;14(2):e1002225.

  53. 53.

    van Katwyk S, Jin YP, Trope GE, Buys Y, Masucci L, Wedge R, et al. Cost-utility analysis of extending public health insurance coverage to include diabetic retinopathy screening by optometrists. Value Health. 2017;20(8):1034–40.

  54. 54.

    Yang SC, Lai WW, Lin CC, Su WC, Ku LJ, Hwang JS, et al. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. Lung Cancer. 2017;108:183–91.

  55. 55.

    Albright CM, MacGregor C, Sutton D, Theva M, Hughes BL, Werner EF. Group B streptococci screening before repeat cesarean delivery: a cost-effectiveness analysis. Obstet Gynecol. 2017;129(1):111–9.

  56. 56.

    Cressman S, Peacock SJ, Tammemagi MC, Evans WK, Leighl NB, Goffin JR, et al. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. J Thorac Oncol. 2017;12(8):1210–22.

  57. 57.

    Kim JJ, Burger EA, Sy S, Campos NG. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Cancer Inst. 2017;109(2)

  58. 58.

    Lew JB, St John DJB, Xu XM, Greuter MJE, Caruana M, Cenin DR, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lancet Public Health. 2017; https://doi.org/10.1016/S2468-2667(17)30105-6.

  59. 59.

    Pil L, Hoorens I, Vossaert K, Kruse V, Tromme I, Speybroeck N, et al. Cost-effectiveness and budget effect analysis of a population-based skin cancer screening. JAMA Dermatol. 2016; https://doi.org/10.1001/jamadermatol.2016.4518.

  60. 60.

    Roberts K, Cannon J, Atkinson D, Brown A, Maguire G, Remenyi B, et al. Echocardiographic screening for rheumatic heart disease in indigenous Australian children: a cost-utility analysis. J Am Heart Assoc. 2017;6(3):e004515. https://doi.org/10.1161/JAHA.116.004515.

  61. 61.

    Sharma M, Seoud M, Kim JJ. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: an example from Lebanon. Vaccin. 2017;35(4):564–9.

  62. 62.

    Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for helicobacter pylori infection: cost-utility analysis by age, sex and ethnicity. BMC Infect Dis. 2017;17(1):156.

  63. 63.

    Kim JJ, Burger EA, Sy S, Campos NG. Optimal cervical cancer screening in women vaccinated against human papillomavirus. 2017.

  64. 64.

    Rodriguez-Perez MC, Orozco-Beltran D, Gil-Guillen V, Dominguez-Coello S, Almeida-Gonzalez D, Brito-Diaz B, et al. Clinical applicability and cost-effectiveness of DIABSCORE in screening for type 2 diabetes in primary care. Diabetes Res Clin Pract. 2017;130:15–23.

  65. 65.

    Selvapatt N, Ward T, Harrison L, Lombardini J, Thursz M, McEwan P, et al. The cost impact of outreach testing and treatment for hepatitis C in an urban drug treatment unit. Liver Int. 2017;37(3):345–53.

  66. 66.

    Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatol. 2017;65(4):1237–48.

  67. 67.

    van Luijt PA, Heijnsdijk EA, de Koning HJ. Cost-effectiveness of the Norwegian breast cancer screening program. Int J Cancer. 2017;140(4):833–40.

  68. 68.

    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, et al. A cost-utility analysis of prostate cancer screening in Australia. Appl Health Econ Health Policy. 2017;15(1):95–111.

  69. 69.

    Ferguson TW, Tangri N, Tan Z, James MT, Lavallee BDA, Chartrand CD, et al. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective. Kidney Int. 2017;92(1):192–200.

  70. 70.

    Chevalier L, Kervio G, Doutreleau S, Mathieu JP, Guy JM, Mignot A, et al. The medical value and cost-effectiveness of an exercise test for sport preparticipation evaluation in asymptomatic middle-aged white male and female athletes. Arch Cardiovasc Dis. 2017;110(3):149–56.

  71. 71.

    Htet KK, Liabsuetrakul T, Thein S. Cost-effectiveness of a new strategy to detect pulmonary tuberculosis in household contacts in Myanmar. Int J Tuberc Lung Dis. 2017;21(2):181–7.

  72. 72.

    Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. Eur J Clin Microbiol Infect Dis. 2017;36(6):1047–55.

  73. 73.

    Smit GS, Apers L, Arrazola de Onate W, Beutels P, Dorny P, Forier AM, et al. Cost-effectiveness of screening for active cases of tuberculosis in Flanders, Belgium. Bull World Health Organ. 2017;95(1):27–35.

  74. 74.

    Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for methicillin-resistant Staphylococcus aureus prevention in adult ICUs: a cost-effectiveness analysis. Crit Care Med. 2017;45(8):1304–10.

  75. 75.

    Baggaley RF, Irvine MA, Leber W, Cambiano V, Figueroa J, McMullen H, et al. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Lancet HIV. 2017;4(10):e465–e74.

  76. 76.

    Cheng X, Zhao Y, Zhang X, Jin H, Min J. Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population. Hum Vaccin Immunother. 2017;13(8):1873–8.

  77. 77.

    Liow MHL, Agrawal K, Anderson DW, Freiberg AA, Rubash HE, Kwon YM. Unsuspected malignancies in routine femoral head histopathologic examination during primary total hip arthroplasty: cost-effectiveness analysis. J Arthroplast. 2017;32(3):735–42.

  78. 78.

    Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017;28(2):643–52.

  79. 79.

    Wrenn SM, Callas PW, Abu-Jaish W. Histopathological examination of specimen following cholecystectomy: are we accepting resect and discard? Surg Endosc. 2017;31(2):586–93.

  80. 80.

    Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. Congenital toxoplasmosis in Austria: prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis. 2017;11(7):e0005648.

  81. 81.

    Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. Centre for Health Economics; 2010. p. RP54.

  82. 82.

    Bojke L, Spackman E, Hinde S, Helliwell P. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatol (Oxford). 2012;51(2):210–5.

  83. 83.

    Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24(4):751–73.

  84. 84.

    Spackman E, Hinde S, Bojke L, Payne K, Sculpher M. Using cost-effectiveness analysis to quantify the value of genomic-based diagnostic tests: recommendations for practice and research. Genet Test Mol Biomarkers. 2017;21(12):705–16.

  85. 85.

    Borkent-Raven BA, Janssen MP, van der Poel CL, Bonsel GJ, van Hout BA. Cost-effectiveness of additional blood screening tests in the Netherlands. Transfusion. 2012;52(3):478–88.

Download references

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Authors’ contributions

Both authors contributed to (i) the conception of the review, (ii) data extraction and analysis, and (iii) manuscript drafting and revising. The authors agree to be accountable for all aspects of this work. Both authors approve this version to be published.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Correspondence to Eldon Spackman.

Appendices

Appendix 1

Table 3 EMBASE search strategy

Appendix 2

Table 4 MEDLINE search strategy

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Screening
  • Cost-effectiveness analysis
  • Value
  • Pre-symptomatic disease